All editions

Search results (10)

12 Apr 2022

ESMO Breast Cancer 2022: Prof. Delaloge - Let’s discuss all the major advances

Watch video

Breast Cancer

3 May 2022

Optimising adjuvant treatment in HR+/HER2-negative early breast cancer

Gene-expression assays have produced a huge step forward in identifying patients who are likely to benefit from adjuvant chemotherapy but there is still a long way to go in the more specific targeting of treatment

By Joseph A. Sparano

Read more

Personalised medicine

3 May 2022

Is molecular profiling useful in the management of breast cancer?

By
• Harold Burstein - Guest editor

Read more

Anticancer agents & Biologic therapy

4 May 2022

Results suggest the efficacy of trastuzumab deruxtecan is influenced by the spatial distribution of HER2 in breast tumour cells

Read more

Epidemiology/Etiology/Cancer Prevention

3 May 2022

The future of personalised risk-stratified breast cancer screening

Will widespread screening for breast cancer based on individual risk mean the end of the one-size-fits-all standard mammogram?

By Mark E. Robson

Read more

Anticancer agents & Biologic therapy

3 May 2022

Positive patient-reported outcomes data expand on the efficacy benefits of trastuzumab deruxtecan and pembrolizumab

Read more

Anticancer agents & Biologic therapy

3 May 2022

Do CDK4/6 inhibitors affect fertility and are they beneficial in premenopausal women?

Read more

Breast Cancer

3 May 2022

Sibylle Loibl receives the ESMO Breast Cancer 2022 Award

Read more

Breast Cancer

4 May 2022

Combining PARP1 inhibition with an ATR inhibitor does not improve outcomes in pre-treated metastatic TNBC

Read more

Breast Cancer

4 May 2022

Interim analysis shows that the safety of sacituzumab govitecan is in line with expectations

Read more